The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of temsirolimus (Tem) and pazopanib (Paz) in solid tumors with emphasis on renal cell carcinoma (RCC).
T. J. Semrad
No relevant relationships to disclose
C. Eddings
No relevant relationships to disclose
M. P. Dutia
No relevant relationships to disclose
S. Christensen
No relevant relationships to disclose
D. Lau
No relevant relationships to disclose
P. Lara
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - GlaxoSmithKline; Pfizer